Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM Authors: Suzanne V. Arnold, Kensey L. Gosch, Chantal Dolan, Jennifer T. Fine, Ahmad Masri, Sara Saberi, Andrew Wang, Perry M. Elliott, Sheila M. Hegde, Jenny Lam, Amy J. Sehnert, Sharon Cresci, Richard G. Bach, John A. Spertus Published: 2024 Patients with hypertrophic cardiomyopathy (HCM) can have substantial impairments in health status, including exercise intolerance, fatigue, dyspnea, and syncope. Mavacamten reduces ventricular contractility and improves myocardial energetics, resulting in improved echocardiographic parameters,1 exercise capacity,2 and health status.3 We sought to better understand the cross-sectional relationship between echocardiographic-derived measures of cardiac physiology and structure with health status, and the association of changes in echocardiographic parameters over time with concurrent changes in health status. EXPLORER-HCM trial (A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; URL: https://www.clinicaltrials.gov; Unique identifier: NCT03470545) was a double-blind, randomized, placebo-controlled trial of mavacamten versus placebo for 30 weeks in adults with symptomatic obstructive HCM.2 Echocardiograms at baseline and 30 weeks were reviewed by core laboratory personnel blinded to treatment (patients also blinded to echocardiogram results). Patient-reported health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ)4; a heart failure-specific measure validated in HCM.5 Physical limitations, symptoms, quality of life, and social limitations domains are combined into the KCCQ–overall summary score (KCCQ-OS); scores range 0 to 100, where a score is better if it’s higher. The protocol was approved by a central or site-specific Institutional Review Board; all patients provided written informed consent. The data that support the findings of this study are available from Bristol Myers Squibb upon reasonable request. This analysis had 2 aims: (1) examine the cross-sectional associations of echocardiographic parameters with health status at baseline; and (2) examine the longitudinal associations of changes in echocardiographic parameters with changes in health status from baseline to 30 weeks. For cross-sectional analyses, we constructed multivariable linear regression models to explore the association of each echocardiographic parameter with KCCQ-OS, adjusted for age, sex, systolic blood pressure, and body mass index. For longitudinal analyses, models included only the baseline value for each echocardiographic parameter and baseline KCCQ-OS. For each echocardiographic parameter, a nonlinear association with KCCQ-OS was tested using restricted cubic splines. Splines were included for all other continuous variables for adjustment. Between 2018 and 2019, 251 adults with symptomatic obstructive HCM from 68 clinics in 13 countries were enrolled in EXPLORER-HCM. The analytic cohort included 196 (78%) who completed baseline KCCQ (mean age, 57.9±12.2 y; 39% women; mean interventricular septum thickness, 16.9±2.6 mm; peak left ventricular outflow tract [LVOT] gradient, 51.5±29.9 mm Hg at rest, 73.5±31.5 mm Hg with Valsalva, and 85.0±35.2 mm Hg postexercise). The mean KCCQ-OS was 66.6±18.4 at baseline and 76.3±18.5 at 30 weeks. In cross-sectional models, only interventricular septum wall thickness was associated with KCCQ-OS (1.2-point lower KCCQ-OS per mm wall thickness [95% CI –2.2 to –0.2]; P=0.015). In longitudinal models accounting for baseline KCCQ-OS and the associated baseline echocardiographic parameter, changes in several parameters from baseline to 30 weeks were associated with changes in KCCQ-OS (Figure). Association of change in echocardiographic parameter with change in KCCQ-OS from baseline to 30 weeks. A, Peak LVOT gradient at rest. B, Peak left ventricular outflow gradient with Valsalva. C, Peak LVOT gradient postexercise. D, Interventricular septum wall thickness. Solid lines represent the expected changes in KCCQ-OS per unit change in echocardiographic parameter. Dotted lines represent 95% CI around that estimate. P values reflect the statistical significance of the association of each echocardiographic change parameter with change in KCCQ-OS. All models adjusted for baseline KCCQ-OS and baseline echocardiographic parameter; restricted cubic splines tested for nonlinearity and only significant for IVST (P=0.019). Echocardiographic parameters for which changes were not significantly associated with changes in KCCQ-OS included: LV ejection fraction (P =0.12), LV stroke volume (LV end-diastolic volume – LV end-systolic volume; P =0.99), E/e’ septal (P=0.71), E/e’ lateral (P=0.64), E/e’ average (P=0.64), left atrial volume index (P =0.20), posterior wall thickness (P=0.07), relative wall thickness (P=0.29), and resolution of systolic anterior motion of the mitral valve (P=0.41). IVST indicates interventricular septum thickness; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire–Overall Summary score; LV, left ventricular; and LVOT, left ventricular outflow tract. In this mechanistic analysis from the EXPLORER-HCM trial, we found few echocardiographic factors were cross-sectionally associated with health status. This may be due to narrow distributions of baseline echocardiographic variables introduced by the trial inclusion criteria. Furthermore, while cardiac patients often have health status decrements, it can be challenging to identify anatomic or physiologic factors associated with worse or better health status cross-sectionally, because other patient-centered factors (eg, socioeconomic status, depression) may impact patients’ symptoms and quality of life. This is less of an issue when examining changes in anatomy or physiology over time, where patients serve as their own control. Notably, in longitudinal analyses, declines in the peak LVOT gradient at rest, with Valsalva, and postexercise were each associated with improvements in health status, with declines in resting gradients appearing to have the strongest association. This may be due to resting gradients being more representative than provocable gradients of patients’ routine activities. Additionally, decreases in interventricular septum wall thickness were associated with improvements in health status. Because of the complex relationship between wall thickness and dynamic LVOT gradients in obstructive HCM, the interplay between physiologic and anatomic changes and changes in health status is challenging to disentangle. Contrary to our original hypothesis, measures of diastolic function were not significantly associated with health status, either cross-sectionally or longitudinally. Future studies, with larger cohorts, should further examine these associations in patients with nonobstructive HCM. Potential limitations to our study include the exclusion of treatment in the models, to avoid it serving as a marker of physiologic changes. This could be a confounder, however, if there are mechanisms of benefit in myosin inhibition beyond the effect on cardiac physiology and anatomy. Additionally, although the echocardiograms were performed using standardized protocols and analyzed at a core laboratory, all parameters have potential error, and some parameters may even change according to patients’ volume statuses. Both factors increase noise in the measurement, making it more challenging to identify associations between these parameters and health status. In conclusion, in patients with obstructive HCM, the most important anatomic and physiologic changes associated with changes in patients’ health status are the magnitude of LVOT obstruction and septal hypertrophy. These data provide novel insights to inform future studies to define how such anatomic and physiologic measures may better support patient selection for treatment with cardiac myosin inhibitors. ARTICLE INFORMATION Acknowledgments Dr Arnold: conceptualization, methodology, interpretation, writing-original draft; K.L. Gosch: methodology, formal analysis, interpretation, writing review and editing; Dr Dolan: conceptualization, methodology, interpretation, writing review and editing, project administration; Drs Fine, Lam, and Sehnert: conceptualization, writing review and editing, project administration; Drs Masri, Saberi, Wang, Elliot, Hegde, Cresci, and Bach: conceptualization, interpretation, writing review and editing; JAS: conceptualization, methodology, interpretation, writing review and editing. Dr Arnold and K.L. Gosch had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Sources of Funding The study was funded by MyoKardia, a wholly owned subsidiary of Bristol Myers Squibb. Co-authors employed by the funder were involved in study design, data interpretation, and review of the manuscript, in collaboration with academic coauthors. All analyses were performed independently by the academic coauthors. Authors had final responsibility for the decision to submit for publication. Disclosures Dr Dolan reports consultant fees from MyoKardia, Genentech, Puma Biotechnology, Gilead Sciences, Alexion Pharmaceuticals, Portola Pharmaceuticals, Halozyme Therapeutics, Global Blood Therapeutics, and REGENXBIO. Dr Fine is an employee of Bristol Myers Squibb at the time of this article development; and reports stock and stock options from the company. Dr Masri reports research grants from Pfizer, Akcea, Ionis, Ultromics, and the Wheeler Foundation; as well as fees (consulting or honoraria) from Eidos, Pfizer, Ionis, Bristol Myers Squibb, Attralus, Tenaya, Alnylam, and Cytokinetics. Dr Saberi reports consulting fees from MyoKardia and Cytokinetics. Dr Wang reports consultant fees from MyoKardia and personal fees from Cytokinetics. Dr Elliot reports consultant and personal fees from MyoKardia, Sanofi, AstraZeneca, Pfizer, and DinaQor; and patent No. GB1815111.8 issued to his institution. Dr Hegde reports that her institution received payments for her consulting work from MyoKardia. Drs Lam and Sehnert are employees of Bristol Myers Squibb and report stock and stock options from the company. Dr Cresci reports that her institution received clinical trial funding from Imbria Pharmaceuticals; and membership on the Data Monitoring Committee for Cytokinetics. Dr Bach reports institutional funding for clinical trials by MyoKardia/Bristol Myers Squibb and Cytokinetics. Dr Spertus reports consultative services on patient-reported outcomes and evidence evaluation for Alnylam, AstraZeneca, Bayer, Merck, Janssen, Bristol Meyers Squibb, Edwards, Kineksia, 4DT Medical, Terumo, Cytokinetics, Imbria, and United Healthcare. He holds research grants from Bristol Meyers Squibb, Abbott Vascular, and Janssen. He owns the copyright to the Seattle Angina Questionnaire, Kansas City Cardiomyopathy Questionnaire, and Peripheral Artery Questionnaire and serves on the Board of Directors for Blue Cross Blue Shield of Kansas City. The other authors report no disclosures.